Evidence map›Paper›PMID 28210673›Full record

ReviewCellular and molecular gastroenterology and hepatology2015

Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.

Mark Kidd, Irvin M Modlin, Lisa Bodei, Ignat Drozdov

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular gastroenterology and hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Cells · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  11. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2020
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Pathophysiology of Gastric NETs: Role of Gastrin and Menin.Current gastroenterology reports · 2017
    Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mark KiddThe Gnostic Consortium, Wren Laboratories, Branford, Connecticut.
Irvin M ModlinThe Gnostic Consortium, Wren Laboratories, Branford, Connecticut.
Lisa BodeiThe Gnostic Consortium, Wren Laboratories, Branford, Connecticut.
Ignat DrozdovThe Gnostic Consortium, Wren Laboratories, Branford, Connecticut.
Wren Laboratories (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), considered a heterogeneous neoplasia, exhibit ill-defined pathobiology and protean symptomatology and are ubiquitous in location. They are difficult to diagnose, challenging to manage, and outcome depends on cell type, secretory product, histopathologic grading, and organ of origin. A morphologic and molecular genomic review of these lesions highlights tumor characteristics that can be used clinically, such as somatostatin-receptor expression, and confirms features that set them outside the standard neoplasia paradigm. Their unique pathobiology is useful for developing diagnostics using somatostatin-receptor targeted imaging or uptake of radiolabeled amino acids specific to secretory products or metabolism. Therapy has evolved via targeting of protein kinase B signaling or somatostatin receptors with drugs or isotopes (peptide-receptor radiotherapy). With DNA sequencing, rarely identified activating mutations confirm that tumor suppressor genes are relevant. Genomic approaches focusing on cancer-associated genes and signaling pathways likely will remain uninformative. Their uniquely dissimilar molecular profiles mean individual tumors are unlikely to be easily or uniformly targeted by therapeutics currently linked to standard cancer genetic paradigms. The prevalence of menin mutations in pancreatic NEN and P27

Indexed as

5-HT, serotonin, 5-hydroxytryptamineAkt, protein kinase BBloodBRAF, gene encoding serine/threonine-protein kinase B-RafcAMP, adenosine 3′,5′-cyclic monophosphateCarcinoidCgA, chromogranin ACGH, comparative genomic hybridizationCREB, cAMP response element-binding proteinDAG, diacylglycerolD cell, somatostatinEC, enterochromaffinECL, enterochromaffin-likeEGFR, epidermal growth factor receptorERK, extracellular-signal-regulated kinaseGABA, γ-aminobutyric acidGastroenteropancreatic Neuroendocrine NeoplasmsG cell, gastrinGEP-NEN, gastroenteropancreatic neuroendocrine neoplasmsGPCR, G-protein coupled receptorIGF-I, insulin-like growth factor-IISG, immature secretory vesiclesKi-67LOH, loss of heterozygosityMAPK, mitogen-activated protein kinaseMEN-1/MEN1, multiple endocrine neoplasia type 1miR/miRNA, micro-RNAMSI, microsatellite instabilityMTA, metastasis associated-1mTOR, mammalian target of rapamycinNEN, neuroendocrine neoplasmsNFκB, nuclear factor κBPET, positron emission tomographyPI3K, phosphoinositide-3 kinasePI3, phosphoinositide-3PKA, protein kinase APKC, protein kinase CProliferationPTEN, phosphatase and tensin homolog deleted on chromosome 10SD-208, 2-(5-chloro-2-fluorophenyl)-4-[(4-pyridyl)amino]p-teridineSNV, single-nucleotide variantSomatostatinSSA, somatostatin analogSST, somatostatinTGF, transforming growth factorTGN, trans-Golgi networkTranscriptomeTSC2, tuberous sclerosis complex 2 (tuberin)VMAT, vesicular monoamine transportersX/A-like cells, ghrelin

Identifiers

PMID28210673
PMCPMC5301133
OpenAlexW2044728344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.